JAMA:肾移植受者应接种三剂mRNA-1273 SARS-CoV-2疫苗

2021-07-26 MedSci原创 MedSci原创

器官移植受者可考虑使用第三剂疫苗。

研究报告称,接受mRNA新型冠状病毒疫苗的固体器官移植受者的血清转换率较低(第二剂后为58%).基于这一证据,法国国家卫生局在2021年4月发布了一项建议,对接种2剂后没有反应的免疫抑制患者接种第三剂疫苗。

Ilies Benotmane等检查了肾移植受者的抗体反应,这些受者对两剂没有反应,并接受了第三剂(100μg)mRNA-1273疫苗(Moderna)。研究结果发表在JAMA杂志。

所有的肾移植受者在2021年1月20日至2021年6月3日期间在斯特拉斯堡大学医院门诊肾移植科进行随访,在第一次注射疫苗当天和第二次注射疫苗后1个月,COVID-19和SARS-CoV-2抗鼠疫IgG水平均低于50个任意单位(AU)/mL。所有患者在2021年4月9日至2021年5月12日期间接受了第三剂疫苗。第三剂量疫苗后的抗受体结合域IgG反应采用ARCHITECT IgG II定量试验(Abbott)进行评估。滴度大于50 AU/mL被视为阳性(检测范围为6.8-80)000金/毫升;肯定一致,99.4%;否定同意,99.6%)。本试验结果已被证明与SARS-CoV-2的体外中和作用相关。表中因素的调整平均差异使用一般线性模型计算。

第二剂疫苗后一个月,159名肾移植受者的IgG水平低于50 Au/ml。中位年龄为57.6岁(四分位数范围[IQR],49.6-66.1岁),61.6%为男性,中位移植时间为5.3年(IQR,1.9-11.1年)(表)。95例(59.7%)在2剂后无抗体反应(滴度<6.8Au/ml),64例(40.3%)抗体反应低于阳性限度(滴度6.8~49.9Au/ml)。第三剂在第二剂后中位注射51天(IQR,48-59天)。在第三次疫苗注射后28天(IQR,27-33天)中位数测量抗体应答,78名患者(49%)的抗体水平大于50 Au/ml(应答者的抗体滴度中位数,586 Au/ml;IQR,197.2-1920.1 Au/ml)。

与无抗体应答者相比,第二剂后应答弱的患者在第三剂后发生抗体应答的可能性更大(分别为81.3%和27.4%;平均校正抗体滴度差894.89Au/ml[95%CI,377.41-1410.37];P=0.001)。服用他克莫司、霉酚酸盐和类固醇的患者比其他方案治疗的患者更不可能产生抗SARS-CoV-2抗体(分别为35%和63%;平均调整抗体滴度差,-697.28 Au/ml[95%CI,-1193.00至-201.56];P=0.006)。与抗体滴度相关的其他变量如表所示。第三剂后未观察到严重不良事件。

这项研究发现,第三剂mRNA-1273疫苗在49%的肾移植受者(这些受者在两剂后没有反应)中诱导了血清学反应。这一大组肾移植受者的发现与其他实体器官移植受者的研究一致。然而,51%的患者在第三剂后没有产生抗SARS-CoV-2抗体,尤其是接受三联免疫抑制的患者。没有评估患者产生细胞免疫能力对严重疾病提供保护的可能性。然而,在一些接种疫苗的移植受者中出现严重的新冠肺炎可能表明缺乏免疫能力。综上所述,器官移植受者可考虑使用第三剂疫苗。

原文出处

Benotmane I, Gautier G, Perrin P, et al. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA. Published online July 23, 2021. doi:10.1001/jama.2021.12339

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938025, encodeId=d5d2193802509, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Mar 26 16:11:02 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822608, encodeId=5b3b1822608ae, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 30 01:11:02 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321292, encodeId=24eb132129269, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559882, encodeId=10a115598825a, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565891, encodeId=19b01565891f6, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036769, encodeId=964e1036e695f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249599, encodeId=a1b91249599eb, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2022-03-26 hukaixun
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938025, encodeId=d5d2193802509, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Mar 26 16:11:02 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822608, encodeId=5b3b1822608ae, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 30 01:11:02 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321292, encodeId=24eb132129269, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559882, encodeId=10a115598825a, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565891, encodeId=19b01565891f6, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036769, encodeId=964e1036e695f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249599, encodeId=a1b91249599eb, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938025, encodeId=d5d2193802509, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Mar 26 16:11:02 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822608, encodeId=5b3b1822608ae, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 30 01:11:02 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321292, encodeId=24eb132129269, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559882, encodeId=10a115598825a, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565891, encodeId=19b01565891f6, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036769, encodeId=964e1036e695f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249599, encodeId=a1b91249599eb, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2021-07-27 小刀医生
  4. [GetPortalCommentsPageByObjectIdResponse(id=1938025, encodeId=d5d2193802509, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Mar 26 16:11:02 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822608, encodeId=5b3b1822608ae, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 30 01:11:02 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321292, encodeId=24eb132129269, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559882, encodeId=10a115598825a, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565891, encodeId=19b01565891f6, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036769, encodeId=964e1036e695f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249599, encodeId=a1b91249599eb, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1938025, encodeId=d5d2193802509, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Mar 26 16:11:02 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822608, encodeId=5b3b1822608ae, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 30 01:11:02 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321292, encodeId=24eb132129269, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559882, encodeId=10a115598825a, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565891, encodeId=19b01565891f6, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036769, encodeId=964e1036e695f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249599, encodeId=a1b91249599eb, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1938025, encodeId=d5d2193802509, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Mar 26 16:11:02 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822608, encodeId=5b3b1822608ae, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 30 01:11:02 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321292, encodeId=24eb132129269, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559882, encodeId=10a115598825a, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565891, encodeId=19b01565891f6, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036769, encodeId=964e1036e695f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249599, encodeId=a1b91249599eb, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2021-07-26 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1938025, encodeId=d5d2193802509, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Mar 26 16:11:02 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822608, encodeId=5b3b1822608ae, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Sun Jan 30 01:11:02 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321292, encodeId=24eb132129269, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559882, encodeId=10a115598825a, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565891, encodeId=19b01565891f6, content=<a href='/topic/show?id=853182620c7' target=_blank style='color:#2F92EE;'>#肾移植受者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82620, encryptionId=853182620c7, topicName=肾移植受者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4715034237, createdName=hjwang84, createdTime=Tue Jul 27 16:11:02 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036769, encodeId=964e1036e695f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249599, encodeId=a1b91249599eb, content=<a href='/topic/show?id=a410122250d' target=_blank style='color:#2F92EE;'>#mRNA-1273#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12225, encryptionId=a410122250d, topicName=mRNA-1273)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon Jul 26 04:11:02 CST 2021, time=2021-07-26, status=1, ipAttribution=)]

相关资讯

J Am Soc Nephrol:肾移植后患者的脑血流、神经化学物质和白质完整性恢复正常。

CKD患者的某些脑异常是可逆的,肾移植后可恢复正常。需要进一步的研究来了解这些脑部异常的机制,并探索干预措施来减轻这些异常,即使是不能移植的患者。

JAMA Surgery:肾移植受者早期皮质类固醇戒断与长期皮质类固醇治疗对于疾病预后的影响

肾移植患者需要进行终生的免疫抑制药物的治疗,以防止排斥反应的发生。最常见的免疫抑制的药物分为3类,分别为钙调神经磷酸酶抑制剂(环孢素或他克莫司),麦考酚酸或硫唑嘌呤和皮质类固醇。

Eur Radiol:肾移植后,如何发现移植肾亚临床病理改变?

血清肌酐测量是一种非常有用和广泛使用的临床工具,快速和无创评估肾移植。然而,肌酐由于敏感性较低,尤其在亚临床病理情况下,肌酐价值有限。

Kidney Int:免疫检查点抑制剂在肾移植癌症患者中的安全性和有效性的多中心研究

免疫检查点抑制剂(ICI)广泛用于各种恶性肿瘤。然而,其在肾移植患者中的安全性和有效性还不明确。

J Am Soc Nephrol:抗IL-6抗体clazakizumab对抗体介导的排斥反应的有利作用

晚期的抗体介导的排斥反应(ABMR)是移植失败的主要原因。阻断IL-6已被认为是一种很有前途的治疗策略。

Sci Rep:肾移植后腰臀比变化对心血管结果的影响

最近有报道称,腰臀比(WHR)能比体重指数(BMI)更好的预测心血管结果。